Skip Nav Destination
Issues
1 January 2013
-
Cover Image
Cover Image
Young and colleagues show that oncogenic and wild-type RAS isoforms have nonredundant, independent roles in cancer cells. Oncogenic RAS isoforms desensitize cells to receptor tyrosine kinase (RTK) stimulation and promote basal mitogen-activated protein kinase (MAPK) signaling, whereas wild-type RAS isoforms are required for RTK-dependent activation of MAPK signaling and optimal growth of cancer cells expressing oncogenic RAS. Depletion of oncogenic RAS sensitizes cells to wild-type isoform-mediated growth factor signaling, uncovering a potential resistance mechanism employed by RAS-mutant cells. Combined inhibition of RAS and RTK signaling effectively blocks growth of cells expressing oncogenic RAS and may therefore be a potential approach to circumvent resistance. For details, please see the article by Young and colleagues on page 112. - PDF Icon PDF LinkTable of Contents
ISSN 2159-8274
EISSN 2159-8290
Issue Sections
In This Issue
In the Spotlight
Prospective
Mini Review
Research Brief
Research Articles
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors
Janneke E. Jaspers; Ariena Kersbergen; Ute Boon; Wendy Sol; Liesbeth van Deemter; Serge A. Zander; Rinske Drost; Ellen Wientjens; Jiuping Ji; Amal Aly; James H. Doroshow; Aaron Cranston; Niall M.B. Martin; Alan Lau; Mark J. O'Connor; Shridar Ganesan; Piet Borst; Jos Jonkers; Sven Rottenberg
The mTORC1 Inhibitor Everolimus Prevents and Treats Eμ-Myc Lymphoma by Restoring Oncogene-Induced Senescence
Meaghan Wall; Gretchen Poortinga; Kym L. Stanley; Ralph K. Lindemann; Michael Bots; Christopher J. Chan; Megan J. Bywater; Kathryn M. Kinross; Megan V. Astle; Kelly Waldeck; Katherine M. Hannan; Jake Shortt; Mark J. Smyth; Scott W. Lowe; Ross D. Hannan; Richard B. Pearson; Ricky W. Johnstone; Grant A. McArthur
Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation
Anna Sukhanova; Andrey Gorin; Ilya G. Serebriiskii; Linara Gabitova; Hui Zheng; Diana Restifo; Brian L. Egleston; David Cunningham; Tetyana Bagnyukova; Hanqing Liu; Anna Nikonova; Gregory P. Adams; Yan Zhou; Dong-Hua Yang; Ranee Mehra; Barbara Burtness; Kathy Q. Cai; Andres Klein-Szanto; Lisa E. Kratz; Richard I. Kelley; Louis M. Weiner; Gail E. Herman; Erica A. Golemis; Igor Astsaturov
News in Brief
News in Depth
Research Watch
Aneuploidy
Chemotherapy
Clinical Trials
Colorectal Cancer
DNA Repair
Drug Resistance
Epigenetics
Glioblastoma
Glioma
Inflammation
Lung Cancer
Melanoma
Metabolism
Metastasis
Oncogenes
Prostate Cancer
Signaling
Targeted Therapy
Tumor Microenvironment
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.